CME in Minutes: Education in Oncology & Hematology
By Answers in CME
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Answers in CME
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 4
Reviews: 0
Episodes: 171
Description
Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
| Episode | Date |
|---|---|
|
Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies
|
Dec 10, 2025 |
|
Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy
|
Dec 09, 2025 |
|
Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC
|
Dec 08, 2025 |
|
Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care
|
Dec 05, 2025 |
|
Michael Postow, MD - Enhancing First-Line Treatment Selection in Advanced Melanoma: A Patient-Centered Approach
|
Dec 02, 2025 |
|
Mark Awad, MD, PhD / Carl M. Gay, MD, PhD - Breaking News in Small-Cell Lung Cancer: Expert Insights on B7-H3–Directed Antibody–Drug Conjugates From Recent Congresses
|
Dec 01, 2025 |
|
Wells A. Messersmith, MD - Illustrating the Journey to Improved Outcomes for MSI-H/dMMR Metastatic CRC: Bringing Immunotherapy-Based Regimens to the Forefront
|
Nov 28, 2025 |
|
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies
|
Nov 25, 2025 |
|
Luis Paz-Ares, MD, PhD / Lauren Averett Byers, MD - Shaping the Future of SCLC Treatment: Advancing Care Through Innovative Approaches
|
Nov 24, 2025 |
|
Christine Brezden-Masley, MD, PhD, FRCPC - Reducing Risk of Recurrence in HR+, HER2-, High-Risk Early Breast Cancer: Optimizing Risk Stratification and Use of Adjuvant CDK4/6 Inhibitors
|
Nov 21, 2025 |
|
Komal Jhaveri, MD, FACP, FASCO - From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer
|
Nov 20, 2025 |
|
Arielle Elkrief, MD / Normand Canty - Cases in Metastatic NSCLC: Optimizing Long-term Outcomes With Frontline Immunotherapy-Based Regimens
|
Nov 19, 2025 |
|
Arielle Elkrief, MD - Navigating Neoadjuvant, Adjuvant, and Perioperative Immunotherapy in Resectable High-Risk Melanoma: Tailoring Care for Optimal Outcomes
|
Nov 18, 2025 |
|
Alison Sehgal, MD - The Case for CAR T-Cell Therapy in Second-Line R/R LBCL: A Framework for Long-Term Success
|
Nov 06, 2025 |
|
Edward B. Garon, MD, MS - A Case of Best Practices: Optimizing First-Line Chemoimmunotherapy for Advanced Squamous NSCLC
|
Nov 03, 2025 |
|
Luis Paz-Ares, MD, PhD / Kristin Higgins, MD - Creating a Roadmap to Optimize Care for Patients With LS-SCLC: Integrating the Evidence Into Practical Care
|
Oct 30, 2025 |
|
Pasi A. Jänne, MD, PhD, FASCO - Translating the Latest Evidence on First-Line Treatment for EGFR-Mutated NSCLC Into Practice: An Update for Community Clinicians
|
Oct 28, 2025 |
|
Sonia Pernas, MD, PhD / Joyce O'Shaughnessy, MD / Hans Wildiers, MD, PhD - Case-Based Insights Into HER2-Low and -Ultralow Metastatic Breast Cancer: Elevating Patient Outcomes With ADCs
|
Oct 28, 2025 |
|
Barbara Melosky, MD, FRCPC / Hossein Borghaei, DO, MS - Towards Durable Outcomes: Personalizing Frontline Immunotherapy-Based Regimens in Advanced NSCLC
|
Oct 15, 2025 |
|
Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML
|
Oct 03, 2025 |
|
Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6
|
Sep 30, 2025 |
|
Ramez N. Eskander, MD - Selecting the Optimal Regimen for Advanced Endometrial Cancer: A Case-Based, Multidisciplinary Approach
|
Sep 30, 2025 |
|
Justin F. Gainor, MD - A Blueprint for Action: Integrating Pre- and/or Post-Operative Immunotherapy Into Early-Stage NSCLC Management
|
Sep 30, 2025 |
|
Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach
|
Sep 24, 2025 |
|
Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma
|
Sep 22, 2025 |
|
Mona Shafey, MD, FRCPC / Nicole Lamanna, MD - Charting the Course: Navigating the Maze of Treatment Selection and Sequencing in CLL
|
Sep 12, 2025 |
|
David Rees, MA, MBBS, FRCPath, FRCPCH, FRCP - Sickle Cell Disease in Perspective: An Expert Point of View on Therapeutic Selection and Comprehensive Care
|
Sep 12, 2025 |
|
Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes
|
Sep 10, 2025 |
|
Jesus Berdeja, MD - Chartering New Frontiers in Myeloma Care: What Role May Novel CELMoDs Play in Early-Relapse Therapy?
|
Aug 18, 2025 |
|
Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies
|
Aug 13, 2025 |
|
Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation
|
Jul 31, 2025 |
|
Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC
|
Jul 29, 2025 |
|
Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World
|
Jul 28, 2025 |
|
John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors
|
Jul 18, 2025 |
|
Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies
|
Jul 11, 2025 |
|
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations
|
Jul 07, 2025 |
|
Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice
|
Jul 04, 2025 |
|
Thomas Powles, MBBS, MRCP, MD / Jonathan E. Rosenberg, MD - Advancing Urothelial Carcinoma Care With Multidisciplinary Strategies for Clinical Management
|
Jul 03, 2025 |
|
Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors
|
Jul 01, 2025 |
|
Mark A. Socinski, MD - Global Perspectives on Biomarker Testing in NSCLC: Clinical Insights on Optimizing Implementation in Practice
|
Jun 24, 2025 |
|
Venkataraman Raman Muthusamy, MD, MAS - A Window of Opportunity: Identifying the Risk of Esophageal Adenocarcinoma With Prognostic Testing
|
Jun 23, 2025 |
|
Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Optimizing Survivorship Across the Patient Journey, Including Lines of Therapy
|
Jun 17, 2025 |
|
Aditya Bardia, MD / Giuseppe Curigliano, MD, PhD - Sequencing in the Real World With Complex Patient Types, Including Underrepresented Populations
|
Jun 02, 2025 |
|
Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC
|
May 29, 2025 |
|
Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap
|
May 06, 2025 |
|
Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations
|
Apr 16, 2025 |
|
Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer
|
Apr 10, 2025 |
|
Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care
|
Apr 10, 2025 |
|
Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer
|
Apr 04, 2025 |
|
Thomas Martin, MD - Focusing on the Frontline: The Impact of Anti-CD38-Based Quadruplet Regimens for Transplant-Ineligible, Newly-Diagnosed Myeloma
|
Mar 07, 2025 |
|
Arvind Dasari, MD - Leveling Up Care in the Later-Line Treatment of Metastatic Colorectal Cancer: Bringing Quality of Life to the Forefront
|
Jan 31, 2025 |
|
Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes
|
Jan 08, 2025 |
|
Joshua Richter, MD, FACP - Enhancing Outcomes in Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Harnessing Bispecific Antibodies in Community Care
|
Jan 08, 2025 |
|
Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression
|
Jan 02, 2025 |
|
Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer
|
Dec 31, 2024 |
|
Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk
|
Dec 27, 2024 |
|
Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers
|
Dec 17, 2024 |
|
Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types
|
Dec 13, 2024 |
|
David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC
|
Dec 12, 2024 |
|
Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs
|
Dec 02, 2024 |
|
David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC
|
Nov 26, 2024 |
|
David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC
|
Nov 20, 2024 |
|
Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs
|
Nov 15, 2024 |
|
Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment
|
Nov 15, 2024 |
|
Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice
|
Nov 06, 2024 |
|
Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs
|
Oct 30, 2024 |
|
Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma
|
Oct 28, 2024 |
|
Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care
|
Oct 28, 2024 |
|
Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens
|
Sep 19, 2024 |
|
Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease
|
Sep 19, 2024 |
|
David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies
|
Sep 13, 2024 |
|
Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions
|
Sep 09, 2024 |
|
Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization
|
Sep 09, 2024 |
|
John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC
|
Aug 09, 2024 |
|
Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer
|
Aug 09, 2024 |
|
Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease
|
Aug 05, 2024 |
|
Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice
|
Aug 05, 2024 |
|
Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective
|
Jul 12, 2024 |
|
Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice
|
Jul 12, 2024 |
|
Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options
|
Jul 04, 2024 |
|
Ghassan Abou-Alfa, MD, MBA - Getting On the Right Tract: Patient-Centered Strategies to Diagnose Biliary Tract Cancers
|
Jul 04, 2024 |
|
Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease
|
Jul 04, 2024 |
|
Sagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of Therapy
|
Jul 04, 2024 |
|
Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence
|
Jun 25, 2024 |
|
Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens
|
Jun 25, 2024 |
|
Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy
|
Jun 18, 2024 |
|
Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer
|
May 28, 2024 |
|
Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations
|
Apr 30, 2024 |
|
Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician
|
Apr 05, 2024 |
|
Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients
|
Apr 05, 2024 |
|
Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer
|
Apr 05, 2024 |
|
Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males
|
Mar 29, 2024 |
|
Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer
|
Mar 29, 2024 |
|
Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates
|
Mar 25, 2024 |
|
Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens
|
Mar 14, 2024 |
|
Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatment Landscape
|
Mar 08, 2024 |
|
Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors
|
Mar 06, 2024 |
|
Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy
|
Feb 26, 2024 |
|
Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?
|
Feb 26, 2024 |
|
Susana M. Campos, MD, MPH - Expanding the Potential of HER2-Directed Antibody-Drug Conjugates: Evidence and Application in New Tumor Types
|
Feb 22, 2024 |
|
John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies
|
Feb 14, 2024 |
|
Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens
|
Feb 14, 2024 |
|
Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes
|
Jan 10, 2024 |
|
David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy
|
Jan 03, 2024 |
|
Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
|
Jan 03, 2024 |
|
Manish A. Shah, MD - Keeping Current on Frontline Immunotherapy-Chemotherapy Combinations: HER2-Positive and HER2-Negative Unresectable Advanced Gastric or GEJ Adenocarcinoma
|
Dec 29, 2023 |
|
Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
|
Dec 18, 2023 |
|
Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy
|
Dec 18, 2023 |
|
Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach
|
Dec 18, 2023 |
|
Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer
|
Dec 18, 2023 |
|
Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm
|
Dec 05, 2023 |
|
Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors
|
Nov 13, 2023 |
|
Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates
|
Oct 31, 2023 |
|
Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC
|
Oct 11, 2023 |
|
Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches
|
Sep 25, 2023 |
|
Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer
|
Sep 22, 2023 |
|
Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?
|
Sep 19, 2023 |
|
Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies
|
Sep 19, 2023 |
|
Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC
|
Sep 05, 2023 |
|
Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2
|
Sep 05, 2023 |
|
Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies
|
Aug 23, 2023 |
|
Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC
|
Aug 17, 2023 |
|
Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better Pathways of Care
|
Jul 27, 2023 |
|
Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
|
Jul 27, 2023 |
|
Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations
|
Jul 07, 2023 |
|
Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care
|
Jul 03, 2023 |
|
Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?
|
Jul 03, 2023 |
|
Tanios Bekaii-Saab, MD / Kelley A. Rone, DNP, AGNP-c - Providing Holistic Care for Hand-Foot Skin Reaction to Improve Outcomes for Patients on Multikinase Inhibitor Therapy for CRC
|
Jun 27, 2023 |
|
Axel Hauschild, MD - Advancing Outcomes in Surgically Resectable Cutaneous Squamous Cell Carcinoma: Carving New Paths Forward With Immunotherapies
|
Jun 15, 2023 |
|
Sara A. Hurvitz, MD, FACP / Miguel Martín, MD, PhD - Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens
|
Jun 15, 2023 |
|
Javier Cortés, MD / Sarah Donahue, MPH, ANP, AOCNP - Putting Patients First: Optimizing Outcomes via Collaborative Care in Pretreated Advanced Triple Negative Breast Cancer Treatment
|
Jun 12, 2023 |
|
Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations
|
Jun 08, 2023 |
|
Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?
|
May 31, 2023 |
|
Jonathan Schoenfeld, MD, MPH - Evolving the Treatment Landscape in Head and Neck Squamous Cell Carcinoma: Promoting Apoptosis With Emerging Antagonists of Inhibitors of Apoptosis Proteins
|
May 31, 2023 |
|
Suriya Jeyapalan, MD, MPH - Expert Conversations in Newly Diagnosed Glioblastoma: Discussing TTFields as a Recommended Adjuvant Therapeutic Option
|
May 23, 2023 |
|
John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm
|
May 04, 2023 |
|
Hussein Tawbi, MD, PhD / Laura K. Ferris, MD, PhD - Optimizing Outcomes in Advanced Melanoma Through Enhanced Collaboration: A Real-World Multidisciplinary Approach
|
May 04, 2023 |
|
Sergio Giralt, MD, FACP, FASTCT - Charting a New Course in the Treatment Paradigm of Relapsed/Refractory Multiple Myeloma: The Current Snapshot of Novel CAR T-Cell Therapies
|
Apr 21, 2023 |
|
Christine E. Jones, BMBS, PhD - A Full-Throated Appeal to Personalize Care in Advanced Gastroesophageal Junction (GEJ) and Esophageal Cancers: Where Do Immunotherapy-Based Regimens Fit In?
|
Apr 10, 2023 |
|
Reinhard Dummer, Prof. Dr. med - Making the Case for a Systemic Approach to Advanced Basal Cell Carcinoma: A Multidisciplinary Team Strategy to Optimize Long-Term Care
|
Mar 30, 2023 |
|
Giovanni L. Ceresoli - Advancing Care in Advanced Non–Small-Cell Lung Cancer With Combination Locoregional and Systemic Therapies
|
Mar 30, 2023 |
|
Nicolas Girard, MD, PhD - Fortifying Outcomes in Unresectable Stage III Non–Small-Cell Lung Cancer: Current and Evolving Strategies to Optimize the Use of Consolidation Immunotherapy
|
Feb 15, 2023 |
|
Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes
|
Feb 15, 2023 |
|
Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors
|
Feb 15, 2023 |
|
Enriqueta Felip, MD, PhD - Breaking News for Frontline Dual Immunotherapy and Chemotherapy Combination Regimens: Improving Patient Outcomes in Advanced NSCLC
|
Jan 09, 2023 |
|
Omid Hamid, MD - An Expert Conversation About Anti-LAG-3/PD-1 Combinations: Exploring the Clinical Impact of Approved and Emerging Combinations in the Advanced Melanoma Treatment Landscape
|
Dec 20, 2022 |
|
Todd Schlesinger, MD, FAAD - Optimizing Immunotherapy in Patients With Advanced Basal Cell Carcinoma: Practical Strategies to Inform Care
|
Dec 13, 2022 |
|
Suriya Jeyapalan, MD, MPH - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: A Focus on Novel Adjuvant Therapies
|
Dec 13, 2022 |
|
Charles B. Simone, II, MD, FACRO - Thinking Outside the Box to Advance Cancer Care: The Latest Evidence and Guidance on Novel Portable Electric Field Therapies
|
Nov 17, 2022 |
|
Aditya Bardia, MD, MPH - Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?
|
Nov 15, 2022 |
|
Arndt Vogel, MD, PhD - Emerging Trends for Treating Advanced Biliary Tract Cancer: Where Does the Evidence Stand on Immunochemotherapy Combinations
|
Nov 07, 2022 |
|
Eric Jonasch, MD - The Clinical Implications of Current Treatment Options for von Hippel-Lindau Disease
|
Nov 07, 2022 |
|
Samuel L. Washington III, MD, MAS - Bridging the Gap in Prostate Cancer Outcomes for Black Men: Elevating Approaches to Androgen Deprivation Therapy
|
Nov 07, 2022 |
|
Peter R. Galle, MD, PhD - Moving Forward with the Management of Unresectable Hepatocellular Carcinoma: Evaluating the Impact of Emerging First-line Dual Immunotherapy Combination Regimens
|
Oct 28, 2022 |
|
Ghassan Abou-Alfa, MD, MBA - Leveraging Combinatorial Approaches in Hepatocellular Carcinoma: An Exploration of the Clinical Implications of the Available Data
|
Oct 28, 2022 |
|
Javier Cortés, MD, PhD - BRCA Testing in Patients With Early-Stage Breast Cancer: A Focus on the Patient Conversation
|
Oct 24, 2022 |
|
Aiwu Ruth He, MD, PhD - Reshaping the Landscape of Advanced Biliary Tract Cancer: The Evidence for Combination Immunochemotherapy
|
Oct 20, 2022 |
|
Joshua Richter, MD - Charting a New Course in Relapsed/Refractory Multiple Myeloma: The Emergence of BCMA-Targeted Therapies
|
Oct 14, 2022 |
|
Hope S. Rugo, MD, FASCO - Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes with Emerging Antibody Drug Conjugates
|
Oct 04, 2022 |
|
Tanios Bekaii-Saab, MD / Beth McLellan, MD - Managing Hand-Foot Skin Reaction: Interdisciplinary Strategies for Patients on Multikinase Inhibitors
|
Oct 04, 2022 |
|
David Paul Carbone, MD, PhD - Big Advances in Resectable Non–Small-Cell Lung Cancer With Neoadjuvant Immunotherapy
|
Oct 03, 2022 |
|
Sagar Lonial, MD - Rebooting the Treatment of Relapsed/Refractory Multiple Myeloma: A New Look at Novel Cereblon-Targeted Agents
|
Sep 30, 2022 |
|
Shalina Gupta-Burt, MD - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: Personalizing Treatment and Managing Adverse Events
|
Sep 06, 2022 |
|
Orlando M. Gutierrez, MD - Reducing Disparities in Anemia of CKD Management
|
Sep 05, 2022 |
|
George Kassianos, CBE, MD (Hons), FRCGP - A Vaccinator’s Guide to Viral Vector–Based COVID-19 Vaccines
|
Sep 02, 2022 |
|
Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?
|
Aug 31, 2022 |
|
Antonio González Martin, MD, PhD - Exploring the Evolving Role of PD-1/PD-L1 Inhibitors in Cervical Cancer: Setting Sights on Locally Advanced Disease
|
Aug 31, 2022 |
|
Solange Peters, MD, PhD - Harnessing Frontline Dual Immunotherapy and Chemotherapy Combination Regimens for Advanced NSCLC: Strategies to Enhance Individualized Care
|
Aug 23, 2022 |
|
Mary O'Brien, MD, FRCP - Moving Immune Checkpoint Inhibitors to Resected Early-Stage Non-Small Cell Lung Cancer: Emerging Strategies for Adjuvant Therapy
|
Aug 12, 2022 |
|
Barbara Burtness, MD - Rethinking Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Promoting Apoptosis with Emerging Therapies
|
Aug 09, 2022 |
|
Alexander Drilon, MD - Hitting the Mark in Personalizing Oncology Care: A Clinician’s Guide to Best Practices in Biomarker Testing
|
Aug 02, 2022 |